Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.68 |
| ▸ | IL1RN | P18510 | 3/20 | 0.68 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | GHSR | Q92847 | 1/20 | 0.64 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.62 |
| ▸ | ECE1 | P42892 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199418 | 1.00 | ERAP2 (0.68) | ERAP2IL1RNACEGHSRERAP1 | |
| SCHEMBL29993798 | 0.95 | OPRD1 (0.65) | ERAP2IL1RNACEGHSRERAP1 | |
| SCHEMBL30052407 | 0.94 | ACE (0.69) | ACEGHSRECE1 | |
| SCHEMBL30052433 | 0.94 | ACE (0.69) | ACEGHSRECE1 | |
| SCHEMBL30977668 | 0.93 | CCKBR (0.67) | ERAP2IL1RNACEGHSRERAP1 | |
| SCHEMBL30051087 | 0.92 | ACE (0.75) | ERAP2ACEECE1 | |
| SCHEMBL30010730 | 0.91 | ERAP1 (0.66) | ERAP2IL1RNERAP1OPRM1OPRD1 | |
| SCHEMBL30010303 | 0.91 | ERAP1 (0.68) | ERAP2IL1RNERAP1OPRM1OPRD1 | |
| SCHEMBL29577129 | 0.91 | ERAP1 (0.68) | ERAP2IL1RNERAP1OPRM1OPRD1 | |
| SCHEMBL30011658 | 0.91 | ERAP1 (0.66) | ERAP2IL1RNERAP1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | disclosed |